



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q96434

Masaaki HIRANO, et al.

Appln. No.: 10/588,485

Group Art Unit: 1614

Confirmation No.: 8206

Examiner: unknown

Filed: August 4, 2006

For: PROPANE-1, 3-DIONE DERIVATIVE OR SALT THEREOF

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith, except for the following: U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications filed after June 30, 2003.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after

INFORMATION DISCLOSURE STATEMENT
U.S. Appln. No.: 10/588,485
Attorney Docket No. Q96434


filings a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

In compliance with the concise explanation requirement under 37 C.F.R. § 1.98(a)(3) for foreign language documents, Applicant encloses herewith a copy of a Communication from a foreign patent office in a counterpart application citing such documents, together with an English-language version (if not already included) of at least that portion of the Communication indicating the degree of relevance found by the foreign patent office.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,


Mark Boland

Registration No. 32,197

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON DC SUGHRUE/265550

65565
CUSTOMER NUMBER

Date: May 23, 2007

Substitute for Form 1449 A & B/PTO				<i>Complete if Known</i>	
				Application Number	10/588,485
				Confirmation Number	8206
				Filing Date	August 4, 2006
				First Named Inventor	Masaaki HIRANO
				Art Unit	1614
				Examiner Name	unknown
Sheet	1	of	1	Attorney Docket Number	Q96434

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		
		US 6,960,591	B2	11/01/2005	Masaaki HIRANO, et al
		US			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)			
		WO	2002/002533	A1	01/10/2002	Yamanouchi Pharmaceutical Co. Ltd	Abstract

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
		S. BAJUSZ, et al. "HIGHLY POTENT ANTAGONISTS OF LUTEINIZING HORMONE-RELEASING HORMONE FREE OF EDEMATOGENIC EFFECTS"; Proc. Natl. Acad. Sci. USA, vol. 85, pp. 1637-1641, March 1988 .	
		John TRACHTENBERG, et al. "A PHASE 3, MULTICENTER, OPEN LABEL, RANDOMIZED STUDY OF ABARELIX VERSUS LEUPROLIDE PLUS DAILY ANTIANDROGEN IN MEN WITH PROSTATE CANCER"; The Journal of Urology, vol 167, 1670-1674, April 2002, USA	
		Takahito HARA, et al. "SUPPRESSION OF A PITUITARY-OVARIAN AXIS BY CHRONIC ORAL ADMINISTRATION OF A NOVEL NONPEPTIDE GONADOTROPIN-RELEASING HORMONE ANTAGONIST, TAK-013, IN CYNOMOLGUS MONKEYS"; The Journal of Clinical Endocrinology & Metabolism 88(4):1697-1704, April 2003, USA	
		Fabio C. TUCCI, et al. "3-[(2R)-AMINO-2-PHENYLETHYL]-1-(2,6-DIFLUOROBENZYL)-5-(2-FLUORO-3-METHOXYPHENYL)-6-METHYL PYRIMIDIN-2,4-DIONE (NBI 42902) AS A POTENT AND ORALLY ACTIVE ANTAGONIST OF THE HUMAN GONADOTROPIN-RELEASING HORMONE RECEPTOR. DESIGN, SYNTHESIS, AND IN VITRO AND IN VIVO CHARACTERIZATION"; J. Med. Chem. 2005, 48, 1169-1178, USA	

Examiner Signature	Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or follow the hyperlink from the title of the document to the intranet. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to indicate here if English language Translation is attached.